C12N 2760/20252
Relating to complementing cells and packaging systems for producing virus or viral
Official title: relating to complementing cells and packaging systems for producing virus or viral particles
C12N2760/20252 (Relating to complementing cells and packaging systems for producing virus or viral) appears on 7 US grants and 25 published applications in this corpus.
Search patents in C12N- Granted patents
- 7
- Published applications
- 25
- Assignees
- 13
- Inventors
- 48
- Latest grant
- 3 Jun 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 1 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 1 | 1 |
| 2018 | 1 | 3 |
| 2019 | 0 | 0 |
| 2020 | 1 | 1 |
| 2021 | 0 | 0 |
| 2022 | 1 | 2 |
| 2023 | 0 | 2 |
| 2024 | 0 | 6 |
| 2025 | 2 | 2 |
| 2026 | 0 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Enhanced virus-like particles and methods of use thereof for delivery to cells3 Jun 2025US 12,319,938 B2President and Fellows of Harvard College
- Compositions and methods for viral sensitization14 Jan 2025US 12,195,451 B2Ottawa Hospital Research Institute and University of Ottawa
- Compositions and methods for viral sensitization24 May 2022US 11,339,146 B2Ottawa Hospital Research Institute and University of Ottawa
- Compositions and methods for viral sensitization19 May 2020US 10,654,839 B2Ottawa Hospital Research Institute
- LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors8 May 2018US 9,963,718 B2Viratherapeutics GmbH
- Method of producing negative-strand rna virus vector and produced negative-strand rna virus vector27 Aug 2026US 2026/0250709 A1Repli-Tech Co., Ltd.
- Process for producing a purified rhabdovirus from cell culture26 Mar 2026US 2026/0085294 A1Boehringer Ingelheim International GmbH
- Enhanced virus-like particles and methods of use thereof for delivery to cells22 Jan 2026US 2026/0022349 A1The General Hospital Corporation
- Use of engineered jurona virus (jurv) as an oncolytic virus platform for human cancers9 Oct 2025US 2025/0313853 A1BioVentures, LLC
- Modified vero cells and methods of using the same for virus production10 Apr 2025US 2025/0115881 A1Sanofi Pasteur Limited
Most cited
By later US patents
- Purification processes for isolating purified vesicular stomatitis virus from cell culture4US 7,875,446 B2Wyeth · 2011
- Compositions and methods for viral sensitization2US 10,654,839 B2Ottawa Hospital Research Institute · 2020
- LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors1US 9,650,649 B2Viratherapeutics GmbH · 2017